Mohammad Minhajuddin
Overview
Explore the profile of Mohammad Minhajuddin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
2253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sahasrabudhe D, Liesveld J, Minhajuddin M, Singh N, Nath S, Kumar V, et al.
Sci Rep
. 2024 Jun;
14(1):12868.
PMID: 38834690
Acute myeloid leukemia (AML) is fatal in the majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that...
2.
Sheth A, Althoff M, Tolison H, Engel K, Amaya M, Krug A, et al.
Cancer Discov
. 2024 May;
14(10):1922-1939.
PMID: 38787341
Acute myeloid leukemia stem cells (LSCs) are uniquely reliant on oxidative phosphorylation (OXPHOS) for survival. Moreover, maintenance of OXPHOS is dependent on BCL-2, creating a therapeutic opportunity to target LSCs...
3.
Sheth A, Engel K, Tolison H, Althoff M, Amaya M, Krug A, et al.
bioRxiv
. 2023 Oct;
PMID: 37873284
We previously reported that acute myeloid leukemia stem cells (LSCs) are uniquely reliant on oxidative phosphorylation (OXPHOS) for survival. Moreover, maintenance of OXPHOS is dependent on BCL2, creating a therapeutic...
4.
Pei S, Shelton I, Gillen A, Stevens B, Gasparetto M, Wang Y, et al.
Cancer Discov
. 2023 Jun;
13(9):2032-2049.
PMID: 37358260
Significance: These studies identify and characterize a new type of human acute myeloid LSC that is responsible for monocytic disease progression in patients with AML treated with venetoclax-based regimens. Our...
5.
Culp-Hill R, Stevens B, Jones C, Pei S, Dzieciatkowska M, Minhajuddin M, et al.
Metabolites
. 2023 Apr;
13(4).
PMID: 37110126
Recent advances in targeting leukemic stem cells (LSCs) using venetoclax with azacitidine (ven + aza) has significantly improved outcomes for de novo acute myeloid leukemia (AML) patients. However, patients who...
6.
Gutman J, Winters A, Kent A, Amaya M, McMahon C, Smith C, et al.
Haematologica
. 2023 Apr;
108(10):2616-2625.
PMID: 37051756
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary. We designed a...
7.
Amaya M, Inguva A, Pei S, Jones C, Krug A, Ye H, et al.
Blood
. 2021 Sep;
139(4):584-596.
PMID: 34525179
Acute myeloid leukemia (AML) is characterized by the presence of leukemia stem cells (LSCs), and failure to fully eradicate this population contributes to disease persistence/relapse. Prior studies have characterized metabolic...
8.
Ye H, Minhajuddin M, Krug A, Pei S, Chou C, Culp-Hill R, et al.
Cancer Discov
. 2020 Oct;
11(2):500-519.
PMID: 33028621
Due to the disseminated nature of leukemia, malignant cells are exposed to many different tissue microenvironments, including a variety of extramedullary sites. In the present study, we demonstrate that leukemic...
9.
Jones C, Stevens B, Pollyea D, Culp-Hill R, Reisz J, Nemkov T, et al.
Cell Stem Cell
. 2020 Aug;
27(5):748-764.e4.
PMID: 32822582
We previously demonstrated that leukemia stem cells (LSCs) in de novo acute myeloid leukemia (AML) patients are selectively reliant on amino acid metabolism and that treatment with the combination of...
10.
Pei S, Pollyea D, Gustafson A, Stevens B, Minhajuddin M, Fu R, et al.
Cancer Discov
. 2020 Jan;
10(4):536-551.
PMID: 31974170
Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the...